http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006171883-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb68488acc3fdbf2be5b269025131440 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7bb71de6818009a30c6f8327a2d0eff7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2003-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84b29aac6fc7254f69971dc2574fcc42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8e2581614ae9a48469dccc4f3c9bd87 |
| publicationDate | 2006-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2006171883-A1 |
| titleOfInvention | Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope |
| abstract | A Disclosed are methods for detecting and localizing a cell-specific antigen in a mammal, such as a human subject, comprising exposing peripheral blood mononuclear cells (PBMCs) of the mammal to an immunogenic peptide epitope of the antigen, under conditions for antigen-specific activation of T lymphocytes in the PBMCs, thereby producing antigen-specific T lymphocytes that at least bind to the cell-specific antigen. Labeled antigen-specific T lymphocytes are administered to the mammal, typically with-out IL-2, either intraperitoneally or intravenously. The distribution of these cells in the mammal is determined by imaging, thereby detecting and localizing cell-specific antigen in the mammal. Exposing PBMCs to the immunogenic peptide typically involves a cell-free peptide preparation and interleukin-2 (IL-2), but no additional cells such as antigen presenting cells (APC) separately pulsed with antigen. The antigen-specific T lymphocytes typically are cytolytic for cells expressing the cell-specific antigen and may comprise CD4+, CD8+, and/or CD45RO+ memory T cells. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11054534-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007196331-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11300695-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7563459-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007248577-A1 |
| priorityDate | 2002-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 424.